Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis

Qiang Tong, Qing Cai, Tristan De Mooij, Xia Xu, Shengming Dai, Wenchun Qu, Dongbao Zhao

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: This study aims to investigate the prevalence of short-term and long-term adverse events associated with tumor necrosis factor-α (TNF-α) blocker treatment in Chinese Han patients suffering from ankylosing spondylitis (AS). Methods: The study included 402 Chinese Han AS patients treated with TNF-α blockers. Baseline data was collected. All patients were monitored for adverse events 2 hours following administration. Long-term treatment was evaluated at 8, 12, 52 and 104 weeks follow-up for 172 patients treated with TNF-α blockers. Results: Short-term adverse events occurred in 20.15% (81/402), including rash (3.5%; 14/402), pruritus (1.2%; 5/402), nausea (2.2%; 9/402), headache (0.7%; 3/402), skin allergies (4.0%; 16/402), fever (0.5%; 2/402), palpitations (3.0%; 12/402), dyspnea (0.5%; 2/402), chest pain (0.2%; 2/402), abdominal pain (1.0%; 4/402), hypertension (2.2%; 9/402), papilledema (0.5%; 2/402), laryngeal edema (0.2%; 1/402) and premature ventricular contraction (0.2%; 1/402). Long-term adverse events occurred in 59 (34.3%; 59/172) patients, including pneumonia (7.6%; 13/172), urinary tract infections (9.9%; 17/172), otitis media (4.7%; 8/172), tuberculosis (3.5%; 17/172), abscess (1.2%; 2/172), oral candidiasis (0.6%; 1/172), elevation of transaminase (1.7%; 3/172), anemia (1.2%; 2/172), hematuresis (0.6%; 1/172), constipation (2.3%; 4/172), weight loss (0.6%; 1/172), exfoliative dermatitis (0.6%; 1/172). CRP, ESR and disease duration were found to be associated with an increased risk of immediate and long-term adverse events (P<0.05). Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc (P<;0.01). Conclusion: This study reports on the prevalence of adverse events in short-term and long-term treatment with TNF-α blocker monotherapy in Chinese Han AS patients. Duration of disease, erythrocyte sedimentation rate, and c-reactive protein serum levels were found to be associated with increased adverse events with anti-TNF-α therapy. Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc.

Original languageEnglish (US)
Article numbere0119897
JournalPLoS One
Volume10
Issue number3
DOIs
StatePublished - Mar 12 2015

Fingerprint

tumor necrosis factors
Ankylosing Spondylitis
Tumor Necrosis Factor-alpha
therapeutics
Dermatitis
pain
Allergies
Therapeutics
Laryngeal Edema
urinary tract diseases
erythrocyte sedimentation rate
Exfoliative Dermatitis
Oral Candidiasis
otitis media
nausea
Papilledema
constipation
headache
Transaminases
candidiasis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis. / Tong, Qiang; Cai, Qing; De Mooij, Tristan; Xu, Xia; Dai, Shengming; Qu, Wenchun; Zhao, Dongbao.

In: PLoS One, Vol. 10, No. 3, e0119897, 12.03.2015.

Research output: Contribution to journalArticle

Tong, Qiang ; Cai, Qing ; De Mooij, Tristan ; Xu, Xia ; Dai, Shengming ; Qu, Wenchun ; Zhao, Dongbao. / Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis. In: PLoS One. 2015 ; Vol. 10, No. 3.
@article{8d89f1445d8848d191e9123ec571280f,
title = "Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis",
abstract = "Objective: This study aims to investigate the prevalence of short-term and long-term adverse events associated with tumor necrosis factor-α (TNF-α) blocker treatment in Chinese Han patients suffering from ankylosing spondylitis (AS). Methods: The study included 402 Chinese Han AS patients treated with TNF-α blockers. Baseline data was collected. All patients were monitored for adverse events 2 hours following administration. Long-term treatment was evaluated at 8, 12, 52 and 104 weeks follow-up for 172 patients treated with TNF-α blockers. Results: Short-term adverse events occurred in 20.15{\%} (81/402), including rash (3.5{\%}; 14/402), pruritus (1.2{\%}; 5/402), nausea (2.2{\%}; 9/402), headache (0.7{\%}; 3/402), skin allergies (4.0{\%}; 16/402), fever (0.5{\%}; 2/402), palpitations (3.0{\%}; 12/402), dyspnea (0.5{\%}; 2/402), chest pain (0.2{\%}; 2/402), abdominal pain (1.0{\%}; 4/402), hypertension (2.2{\%}; 9/402), papilledema (0.5{\%}; 2/402), laryngeal edema (0.2{\%}; 1/402) and premature ventricular contraction (0.2{\%}; 1/402). Long-term adverse events occurred in 59 (34.3{\%}; 59/172) patients, including pneumonia (7.6{\%}; 13/172), urinary tract infections (9.9{\%}; 17/172), otitis media (4.7{\%}; 8/172), tuberculosis (3.5{\%}; 17/172), abscess (1.2{\%}; 2/172), oral candidiasis (0.6{\%}; 1/172), elevation of transaminase (1.7{\%}; 3/172), anemia (1.2{\%}; 2/172), hematuresis (0.6{\%}; 1/172), constipation (2.3{\%}; 4/172), weight loss (0.6{\%}; 1/172), exfoliative dermatitis (0.6{\%}; 1/172). CRP, ESR and disease duration were found to be associated with an increased risk of immediate and long-term adverse events (P<0.05). Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc (P<;0.01). Conclusion: This study reports on the prevalence of adverse events in short-term and long-term treatment with TNF-α blocker monotherapy in Chinese Han AS patients. Duration of disease, erythrocyte sedimentation rate, and c-reactive protein serum levels were found to be associated with increased adverse events with anti-TNF-α therapy. Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc.",
author = "Qiang Tong and Qing Cai and {De Mooij}, Tristan and Xia Xu and Shengming Dai and Wenchun Qu and Dongbao Zhao",
year = "2015",
month = "3",
day = "12",
doi = "10.1371/journal.pone.0119897",
language = "English (US)",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis

AU - Tong, Qiang

AU - Cai, Qing

AU - De Mooij, Tristan

AU - Xu, Xia

AU - Dai, Shengming

AU - Qu, Wenchun

AU - Zhao, Dongbao

PY - 2015/3/12

Y1 - 2015/3/12

N2 - Objective: This study aims to investigate the prevalence of short-term and long-term adverse events associated with tumor necrosis factor-α (TNF-α) blocker treatment in Chinese Han patients suffering from ankylosing spondylitis (AS). Methods: The study included 402 Chinese Han AS patients treated with TNF-α blockers. Baseline data was collected. All patients were monitored for adverse events 2 hours following administration. Long-term treatment was evaluated at 8, 12, 52 and 104 weeks follow-up for 172 patients treated with TNF-α blockers. Results: Short-term adverse events occurred in 20.15% (81/402), including rash (3.5%; 14/402), pruritus (1.2%; 5/402), nausea (2.2%; 9/402), headache (0.7%; 3/402), skin allergies (4.0%; 16/402), fever (0.5%; 2/402), palpitations (3.0%; 12/402), dyspnea (0.5%; 2/402), chest pain (0.2%; 2/402), abdominal pain (1.0%; 4/402), hypertension (2.2%; 9/402), papilledema (0.5%; 2/402), laryngeal edema (0.2%; 1/402) and premature ventricular contraction (0.2%; 1/402). Long-term adverse events occurred in 59 (34.3%; 59/172) patients, including pneumonia (7.6%; 13/172), urinary tract infections (9.9%; 17/172), otitis media (4.7%; 8/172), tuberculosis (3.5%; 17/172), abscess (1.2%; 2/172), oral candidiasis (0.6%; 1/172), elevation of transaminase (1.7%; 3/172), anemia (1.2%; 2/172), hematuresis (0.6%; 1/172), constipation (2.3%; 4/172), weight loss (0.6%; 1/172), exfoliative dermatitis (0.6%; 1/172). CRP, ESR and disease duration were found to be associated with an increased risk of immediate and long-term adverse events (P<0.05). Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc (P<;0.01). Conclusion: This study reports on the prevalence of adverse events in short-term and long-term treatment with TNF-α blocker monotherapy in Chinese Han AS patients. Duration of disease, erythrocyte sedimentation rate, and c-reactive protein serum levels were found to be associated with increased adverse events with anti-TNF-α therapy. Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc.

AB - Objective: This study aims to investigate the prevalence of short-term and long-term adverse events associated with tumor necrosis factor-α (TNF-α) blocker treatment in Chinese Han patients suffering from ankylosing spondylitis (AS). Methods: The study included 402 Chinese Han AS patients treated with TNF-α blockers. Baseline data was collected. All patients were monitored for adverse events 2 hours following administration. Long-term treatment was evaluated at 8, 12, 52 and 104 weeks follow-up for 172 patients treated with TNF-α blockers. Results: Short-term adverse events occurred in 20.15% (81/402), including rash (3.5%; 14/402), pruritus (1.2%; 5/402), nausea (2.2%; 9/402), headache (0.7%; 3/402), skin allergies (4.0%; 16/402), fever (0.5%; 2/402), palpitations (3.0%; 12/402), dyspnea (0.5%; 2/402), chest pain (0.2%; 2/402), abdominal pain (1.0%; 4/402), hypertension (2.2%; 9/402), papilledema (0.5%; 2/402), laryngeal edema (0.2%; 1/402) and premature ventricular contraction (0.2%; 1/402). Long-term adverse events occurred in 59 (34.3%; 59/172) patients, including pneumonia (7.6%; 13/172), urinary tract infections (9.9%; 17/172), otitis media (4.7%; 8/172), tuberculosis (3.5%; 17/172), abscess (1.2%; 2/172), oral candidiasis (0.6%; 1/172), elevation of transaminase (1.7%; 3/172), anemia (1.2%; 2/172), hematuresis (0.6%; 1/172), constipation (2.3%; 4/172), weight loss (0.6%; 1/172), exfoliative dermatitis (0.6%; 1/172). CRP, ESR and disease duration were found to be associated with an increased risk of immediate and long-term adverse events (P<0.05). Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc (P<;0.01). Conclusion: This study reports on the prevalence of adverse events in short-term and long-term treatment with TNF-α blocker monotherapy in Chinese Han AS patients. Duration of disease, erythrocyte sedimentation rate, and c-reactive protein serum levels were found to be associated with increased adverse events with anti-TNF-α therapy. Long-term treatment with Infliximab was associated with more adverse events than rhTNFR-Fc.

UR - http://www.scopus.com/inward/record.url?scp=84928880653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928880653&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0119897

DO - 10.1371/journal.pone.0119897

M3 - Article

C2 - 25764452

AN - SCOPUS:84928880653

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e0119897

ER -